Eli Lilly and Company
ERK inhibitors
Last updated:
Abstract:
The present invention provides thieno[2,3-c]pyrrol-4-one compounds that inhibit activity of extracellular-signal-regulated kinase (ERK) and may be useful in the treatment of cancer.
Status:
Grant
Type:
Utility
Filling date:
22 May 2019
Issue date:
13 Jul 2021